* The 11dhTxB2 (AspirinWorks®) Test Kit is FDA cleared to determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of acetylsalicylic acid (ASA) effect in apparently healthy individuals post ingestion. For professional use only.

The articles referenced are intended for physician reference only and do not pertain to the 11dhTxB2 Test Kit.

 

• “AspirinWorks® Reference Synopsis”
  Corgenix,

 

• “The Current and Future Landscape of Urinary Thromboxane Testing to Evaluate Atherothrombotic Risk”
  Reviews in Cardiovascular Medicine, 2014

 

• “Thromboxane (11dhTxB2) Case Studies in Internal Medicine”, Boone, Volume 1.
  Corgenix, December 2014

 

• “Thromboxane (11dhTxB2) Case Studies in Internal Medicine”, Boone, Volume 2.
  Corgenix, December 2014

 

• “Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus.”
  Thrombosis Research 2012

 

• “On aspirin treatment but not baseline thromboxane B2 levels predict adverse outcomes in patients with acute coronary syndromes.”
  Journal of Thrombosis and Haemostasis 2012

 

• “New CHARISMA Outcome Study Results Validate Aspirin Effect”
  Corgenix, October 2008

 

• “Guidelines for the Diagnosis, Evaluation, and Management of von Willebrand Disease- Update on Aspirin Resistance”
  Corgenix REAADER, September 2008

 

• “New Insights on the Clinical Significance and Laboratory Assessment of Protein C – Aspirin Resistance in the News”
  Corgenix REAADER, March 2008

 

• “Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events” (HOPE) 
  Circulation, April 9, 2002